A1C Almanac

Main Page

Obstructive Sleep Apnea as the Fourth Pillar of Metabolic Syndrome and Accelerated Aging

Posted

by

dr Dimas Bagus Cahyono Putro, Sp.THT-BKL

Table of Contents
Category: ,
Tags: , , , , , ,

Reviewed by A1C Medical Team

Keywords: Obstructive Sleep Apnea, Metabolic Syndrome, Biological Aging, Cardiometabolic Risk, Artificial Intelligence

Introduction

Metabolic syndrome has long been characterized by a constellation of insulin resistance, dyslipidemia, hypertension, and central obesity, reflecting a systemic breakdown in metabolic homeostasis. Increasingly, however, it has become clear that this framework is incomplete without considering the role of sleep. A growing body of evidence indicates that sleep,  particularly the presence or absence of Obstructive Sleep Apnea (OSA)  is a missing but essential component of metabolic health, acting not simply as a comorbidity but as an upstream driver of metabolic dysfunction.

Historically viewed as a predominantly mechanical disorder of upper airway collapse, OSA is now recognized as a systemic metabolic stressor that amplifies low-grade inflammation, worsens insulin resistance, and accelerates biological aging trajectories. Recurrent cycles of intermittent hypoxia, sleep fragmentation, and sympathetic overactivation initiate and perpetuate pathophysiological cascades that closely mirror, and likely potentiate, the core features of metabolic syndrome. In this context, untreated OSA can be conceptualized as a silent accelerator of cardiometabolic risk and age-related decline.

The rapid evolution of AI-driven health technologies offers a unique opportunity to reframe how we detect and manage this risk. Continuous data streams from wearables, home-based sensors, and digital biomarkers now allow early identification of sleep-disordered breathing patterns linked to metabolic deterioration and vascular aging. By integrating these signals with cardiometabolic markers and longitudinal outcomes, OSA can be repositioned from a secondary complication to a primary pillar of metabolic syndrome and a key modifiable driver of aging biology. This paradigm shift has profound implications for preventive cardiometabolic care, longevity medicine, and the design of personalized, AI-enabled wellness interventions.

Understanding Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a chronic sleep-related breathing disorder defined by recurrent episodes of partial or complete upper airway collapse during sleep, resulting in intermittent hypoxemia, arousals, and pronounced swings in intrathoracic pressure. These recurrent events trigger a cascade of physiological stress responses, including activation of the sympathetic nervous system, oxidative stress, and systemic inflammation, which extend far beyond the upper airway and exert widespread metabolic and cardiovascular effects. From a systems perspective, OSA can therefore be conceptualized as a nocturnal “stress test” that is repeated hundreds of times per night, progressively eroding cardiometabolic homeostasis [1-5].

A central pathophysiological hallmark of OSA is chronic intermittent hypoxia (CIH), characterized by repetitive cycles of oxygen desaturation and reoxygenation. CIH promotes excessive generation of reactive oxygen species, endothelial dysfunction, and mitochondrial injury, creating an oxidative milieu that closely mirrors that seen in metabolic syndrome and type 2 diabetes. In parallel, hypoxia and sleep fragmentation drive sustained sympathetic activation with elevations in catecholamines and cortisol, which acutely increase blood pressure and heart rate and chronically contribute to insulin resistance and impaired glucose tolerance. Experimental and clinical studies consistently demonstrate that increasing OSA severity, quantified by the apnea–hypopnea index, correlates with higher indices of insulin resistance and worsened glycemic control, even after adjusting for adiposity [1,4-6].

Sleep fragmentation and poor sleep architecture in OSA also disrupt neuroendocrine regulation of appetite and energy balance. Patients with OSA show altered circulating levels and signaling of leptin and ghrelin, hormones that are critical for satiety, hunger, and ventilatory control. CIH and recurrent arousals are associated with hyperleptinemia and leptin resistance, as well as elevated ghrelin concentrations, changes that favor increased appetite, positive energy balance, and weight gain. Leptin additionally influences ventilatory drive and upper airway neuromuscular responsiveness, linking disordered metabolism to impaired airway stability and further embedding OSA within a self-reinforcing loop of obesity and respiratory dysfunction [1,7-9].

From an otolaryngologic standpoint, the structural and functional properties of the upper airway are key determinants of OSA susceptibility and severity. Obesity and visceral adiposity promote fat accumulation in peripharyngeal soft tissues, including the tongue, soft palate, and parapharyngeal fat pads, which narrows the lumen and increases pharyngeal collapsibility. Imaging and morphometric studies demonstrate that patients with OSA have greater regional fat deposition around the upper airway and higher critical closing pressures than BMI-matched controls, underscoring that local fat distribution and tissue pressure, rather than body mass index alone, drive airway instability. In addition, craniofacial skeletal configuration, soft palate and tongue morphology, and neuromuscular control of the pharyngeal dilator muscles interact with metabolic factors such as insulin resistance and adipokine signalling to determine whether the airway remains patent or collapses during sleep [2,3,10,11].

These observations support a bidirectional relationship between OSA and metabolic dysfunction. On one hand, OSA-induced CIH, sympathetic overactivity, and sleep disruption precipitate or aggravate insulin resistance, dyslipidemia, and hypertension, the core components of metabolic syndrome. On the other hand, metabolic syndrome, characterized by central obesity, ectopic fat deposition, and altered adipokine profiles, further promotes upper airway narrowing, increased surrounding tissue pressure, and reduced neuromuscular compensation, thereby worsening OSA severity. Within this framework, OSA is not merely a coincidental comorbidity but a dynamic pathophysiological partner in a vicious cycle of cardiometabolic derangement and accelerated aging biology [4-6,10,12].

OSA as the Fourth Pillar of Metabolic Syndrome

Obstructive sleep apnea (OSA) has traditionally been viewed as a comorbid condition clustering around obesity, diabetes, and cardiovascular disease, yet accumulating evidence suggests it functions more accurately as an upstream driver of the metabolic milieu classically labelled as metabolic syndrome. The canonical criteria, abdominal obesity, hyperglycemia, hypertriglyceridemia, and hypertension capture downstream phenotypes of chronic cellular stress, while OSA contributes core pathophysiologic inputs such as intermittent hypoxia, sympathetic overactivation, and sleep fragmentation that initiate and amplify these abnormalities. Large epidemiologic and mechanistic studies demonstrate that OSA is independently associated with insulin resistance, dyslipidemia, elevated blood pressure, and visceral adiposity even after adjustment for body mass index, supporting its role as a pathogenically integral component of the syndrome rather than a coincidental association [6,13-16].

A key axis linking OSA to metabolic syndrome is glucose dysregulation and insulin resistance. Recurrent cycles of intermittent hypoxia activate sympathetic outflow and the hypothalamic–pituitary–adrenal axis, increasing catecholamine and cortisol levels and thereby promoting hepatic glucose output and peripheral insulin resistance. Experimental models and population studies show that indices of OSA severity, including apnea–hypopnea index and hypoxic burden, correlate with decreased insulin sensitivity and higher fasting insulin and glucose levels, independent of adiposity. Proposed mechanisms include hypoxia-induced adipose tissue inflammation, alterations in adipokines, and suppression of AMP-activated protein kinase (AMPK) signalling, which together favour impaired glucose uptake and progression toward type 2 diabetes in both obese and non-obese individuals [13,15,16,].

Hypertension and vascular dysfunction represent a second major interface between OSA and metabolic syndrome. Repetitive apneic events lead to abrupt surges in sympathetic tone, blood pressure, and heart rate, which over time maintain a state of persistent sympathetic overactivity and blunted nocturnal dipping. Concurrent intermittent hypoxia and oxidative stress promote endothelial dysfunction, arterial stiffness, and microvascular damage, key features of the pro-hypertensive and pro-atherogenic phenotype observed in metabolic syndrome. Clinical studies have demonstrated that OSA is independently associated with incident and resistant hypertension, and that the burden of nocturnal hypoxemia predicts blood pressure elevation beyond the contribution of obesity alone [6,13,15,17].

Dyslipidemia in OSA extends beyond simple elevations in triglycerides and low-density lipoprotein (LDL) cholesterol. Intermittent hypoxia upregulates hepatic lipid biosynthetic pathways and impairs clearance of triglyceride-rich lipoproteins, leading to increased very-low-density lipoprotein (VLDL) secretion and hypertriglyceridemia characteristic of metabolic syndrome. Additionally, oxidative stress associated with OSA promotes lipid peroxidation, increased levels of oxidized LDL, and functional impairment of high-density lipoprotein (HDL), including reduced antioxidant and anti-inflammatory capacity, even when HDL concentrations are not markedly altered. These changes render the lipid profile more atherogenic and tightly integrate OSA-driven hypoxic stress with the dyslipidemic component of metabolic syndrome [13,14,18,19].

Central obesity and altered body fat distribution complete the bidirectional loop between OSA and metabolic syndrome. Sleep fragmentation, insufficient sleep duration, and circadian misalignment in OSA disrupt the regulation of appetite and energy balance through changes in leptin, ghrelin, and other neuroendocrine mediators. Short or disturbed sleep has been associated with reduced leptin, increased ghrelin, heightened appetite, and preferential intake of energy-dense foods, promoting positive energy balance and visceral adiposity. Conversely, central and parapharyngeal fat accumulation narrows the upper airway and increases collapsibility, reinforcing OSA severity and creating a self-perpetuating cycle in which metabolic syndrome and OSA co-evolve [6,15,20-23].

OSA and Accelerated Biological Aging

Aging is increasingly conceptualized as the progressive accumulation of molecular and cellular damage driven by oxidative stress, mitochondrial dysfunction, genomic instability, and chronic low-grade inflammation processes that are also prominently activated in obstructive sleep apnea (OSA). In this context, OSA can be understood as a chronic, sleep-dependent “accelerator” of biological aging, in which repetitive cycles of intermittent hypoxia, sleep fragmentation, and sympathetic activation chronically overload cellular defense and repair systems. Epigenetic clock studies using DNA methylation signatures have shown that individuals with moderate-to-severe OSA exhibit epigenetic age acceleration compared with matched controls, and that effective continuous positive airway pressure (CPAP) therapy can partially decelerate this aging signal, directly linking sleep-disordered breathing to molecular markers of biological age [24-26].

Several interconnected mechanisms appear to mediate this accelerated aging phenotype in OSA. Hypoxia–reoxygenation cycles characteristic of chronic intermittent hypoxia promote excessive reactive oxygen species (ROS) production, downregulation of antioxidant pathways, and persistent oxidative stress, which in turn damage mitochondrial function and alter metabolic signaling networks. Telomere biology studies have reported shorter leukocyte telomere length in patients with OSA, with telomere attrition correlating with indices of disease severity such as apnea–hypopnea index and oxygen desaturation index, suggesting that intermittent hypoxia and sleep disruption hasten cellular senescence. These molecular alterations are not merely epiphenomena; they are accompanied by functional changes in vascular, neural, and immune systems that are characteristic of an “aged” phenotype [24,25,27].

Neurocognitive decline represents a key clinical expression of OSA-related accelerated aging. Sleep fragmentation and nocturnal hypoxemia have been associated with impaired function of the glymphatic clearance system, which is responsible for removing metabolic waste products and neurotoxic proteins from the brain interstitium during sleep. Imaging and longitudinal cohort studies indicate that OSA is linked to reduced glymphatic efficiency and altered brain network connectivity, changes that correlate with declines in memory and executive function and may increase vulnerability to neurodegenerative diseases. Importantly, some data suggest that improvement or resolution of OSA is associated with partial restoration of glymphatic function, reinforcing the notion that sleep-disordered breathing is a modifiable driver of neurobiological aging [28,29].

Vascular aging constitutes another critical interface between OSA and accelerated biological aging. Chronic intermittent hypoxia and sleep fragmentation trigger endothelial dysfunction, promote pro-inflammatory and pro-senescent phenotypes in vascular cells, and increase arterial stiffness, hallmarks of vascular aging and atherosclerosis. Experimental models of sleep fragmentation demonstrate increased endothelial senescence-associated secretory phenotypes and structural vessel wall changes, paralleling findings in patients with long-standing OSA who exhibit higher measures of arterial stiffness and subclinical atherosclerosis. These vascular changes integrate with OSA-driven metabolic disturbances to amplify lifetime risk of cardiovascular events and contribute to the appearance of a “biologically older” vasculature than would be expected from chronological age alone [25,30,31].

Taken together, epigenetic age acceleration, telomere attrition, glymphatic dysfunction, and vascular senescence converge to support a model in which untreated OSA acts as a “silent aging multiplier,” magnifying metabolic and cardiovascular risk across the lifespan. Within a longevity and preventive medicine framework, systematic identification and treatment of OSA thus represent high-yield interventions to slow biological aging trajectories, complementing traditional targets such as glycemic control, lipid management, and blood pressure optimization [24,25].

The Role of AI and Precision Prevention

Artificial intelligence (AI)–enabled health technologies are rapidly reshaping the landscape of screening and managing obstructive sleep apnea (OSA), with particular relevance for metabolic and longevity-focused care models. Wearable devices equipped with photoplethysmography (PPG) sensors, inertial measurement units, and pulse oximetry can continuously capture heart rate variability, oxygen saturation, and movement patterns, allowing algorithmic detection of sleep-disordered breathing with clinically meaningful accuracy compared with polysomnography, especially for mild-to-moderate OSA and population-level screening. Parallel advances in acoustic analysis enable AI models to extract discriminative features from snoring and breathing sounds, using techniques such as mel-frequency cepstral coefficients and deep neural networks to automatically classify OSA severity from low-cost microphones and smartphone-based recordings. These approaches collectively lower the barriers to early OSA detection and create longitudinal data streams that can be integrated into precision prevention frameworks [32-36].

Beyond standalone screening, AI and machine learning facilitate multivariate risk prediction by integrating sleep-deprived signals with broader cardiometabolic data. Models that combine demographics, anthropometrics, simple laboratory markers (for example, triglyceride–glucose index, apolipoprotein ratios), and basic physiological metrics such as mean nocturnal heart rate have achieved robust discrimination for moderate-to-severe OSA and are now being embedded into cloud-based and mobile sleep medicine platforms. In a longevity context, these same architectures can be extended to incorporate continuous glucose monitoring, heart rate variability, lipidomics, and inflammatory biomarkers to model OSA-related trajectories of metabolic deterioration and cardiovascular aging. Such multimodal predictive systems support earlier identification of individuals in a “pre-OSA” or high-risk state, where targeted interventions may yield the greatest long-term benefit [37-41].

Digital platforms powered by generative AI further expand the scope of precision prevention by translating complex data into individualized action plans. At the population level, AI-driven pattern recognition can segment users into risk strata based on sleep fragmentation patterns, nocturnal desaturation burden, and coexisting metabolic risk factors, flagging those who warrant formal sleep evaluation or more intensive cardiometabolic workup. At the individual level, integration of wearable sleep data, continuous glucose profiles, and, where available, genomic or polygenic risk information enables the tailoring of interventions that combine airway management, weight reduction strategies, circadian alignment, and optimization of exercise and nutrition. Generative AI chatbots and coaching tools can then deliver adaptive, context-aware behavioural nudges such as guidance on sleep hygiene, meal timing, alcohol intake, and evening screen exposure, reinforced by real-time feedback from the user’s own data [37,39,40,41].

This evolving ecosystem effectively reframes OSA management from late-stage, symptom-driven endeavours into a core component of preventive metabolic medicine and longevity programs. Rather than focusing solely on the relief of snoring and daytime sleepiness, AI-enabled systems position sleep integrity and respiratory stability as continuous, measurable inputs into cardiometabolic risk algorithms and biological aging models. Within such a framework, detecting and mitigating OSA becomes a strategic lever to slow metabolic decline, reduce cardiovascular events, and preserve functional capacity across the lifespan, placing AI-driven OSA surveillance and intervention at the center of next-generation precision prevention [37,39,40,41].

Clinical and Wellness Implications

From a clinical and preventive medicine standpoint, obstructive sleep apnea (OSA) should be regarded as a routine consideration in the assessment of metabolic and cardiovascular risk, particularly within otolaryngology and primary care pathways. ENT physicians are uniquely positioned to identify craniofacial and upper airway risk factors, triage patients for appropriate diagnostic testing (including home sleep apnea testing and polysomnography), and coordinate multidisciplinary management that addresses both airway patency and systemic cardiometabolic burden. As evidence continues to link OSA with a two- to threefold increase in metabolic and cardiovascular conditions, incorporating structured screening tools into ENT and metabolic clinics aligns with a shift toward earlier, upstream intervention [43-45].

Comprehensive OSA management extends well beyond continuous positive airway pressure (CPAP) and surgical interventions. Lifestyle and weight management are central: randomized trials and long-term cohort data show that intensive lifestyle interventions and sustained weight loss produce clinically meaningful reductions in apnea–hypopnea index and, in some cases, partial or complete remission of OSA, along with improvements in insulin resistance and glycemic control. Adjunctive strategies include metabolic optimization through diet patterns such as the Mediterranean diet, structured physical activity, and pharmacologic weight-loss agents, which together can reduce OSA severity and downstream cardiometabolic risk. Chronotherapy and circadian alignment, optimizing sleep timing, light exposure, and meal timing are emerging as additional levers to improve sleep quality, cardiometabolic parameters, and adherence to PAP therapy within integrative care models [42,46-48].

Targeted functional interventions further expand the therapeutic toolkit. Myofunctional therapy and oropharyngeal exercises, designed to strengthen upper airway and orofacial muscles, have shown in randomized trials and systematic reviews that they can reduce OSA symptom intensity and daytime sleepiness and modestly improve respiratory event indices, especially as adjuncts to standard care. In parallel, digital health tools and AI-supported sleep pathways have demonstrated improvements in CPAP adherence, reduced clinician workload, and enhanced patient engagement by providing structured education, remote monitoring, and bidirectional communication channels. Integrating these digital platforms with ENT- and sleep-led care can facilitate personalized follow-up, early troubleshooting, and sustained behaviour change, positioning OSA care squarely within the broader ecosystem of preventive metabolic and longevity medicine [49-51].

At the population level, embedding OSA screening and management into cardiometabolic risk reduction and obesity programs offers a high-yield strategy to improve both longevity and quality of life. Guidelines and implementation studies suggest that systematic identification of high-risk individuals, using symptom questionnaires, anthropometrics, and, increasingly, digitally enabled screening can uncover substantial hidden OSA burden among patients with hypertension, diabetes, and obesity. By coupling OSA diagnosis with structured lifestyle, metabolic, and airway-focused interventions, health systems can reduce cardiovascular events, improve functional status, and potentially slow biological aging trajectories, reinforcing the rationale for treating OSA as a central component of chronic disease prevention rather than an isolated sleep complaint [42-44,46,47].

Conclusion

As the conceptual boundaries between sleep medicine, metabolic disease, and longevity biology continue to dissolve, Obstructive Sleep Apnea (OSA) can no longer be regarded as a peripheral comorbidity but rather as a central, modifiable determinant of cardiometabolic risk and aging trajectory. Positioning OSA as a fourth pillar of metabolic syndrome emphasizes its role as an upstream driver of insulin resistance, dyslipidemia, hypertension, and visceral adiposity, rather than a downstream consequence of these abnormalities. Reframing sleep-disordered breathing as a metabolic input fundamentally reshapes clinical and public health priorities: it invites earlier screening, integrated cardiometabolic–sleep pathways, and targeted interventions that combine airway management, weight optimization, and circadian alignment. For AI-enabled wellness platforms and preventive care models, incorporating high-resolution sleep data, alongside glucose, lipid profiles, blood pressure, and inflammatory markers opens the door to more precise risk stratification and personalized intervention design. In this emerging paradigm, sleep integrity becomes a core biomarker of “cellular youth,” and systematic identification and treatment of OSA represent a critical leverage point for slowing cardiometabolic decline and extending health span.

Reference

  1. Berger S, Polotsky VY. Leptin and Leptin Resistance in the Pathogenesis of Obstructive Sleep Apnea: A Possible Link to Oxidative Stress and Cardiovascular Complications. Oxidative Medicine and Cellular Longevity [Internet]. 2018 Feb 20 [cited 2019 Nov 23];2018:1–8. Available from: https://www.hindawi.com/journals/omcl/2018/5137947/
  2. Themes UFO. Pathophysiology of Obstructive Sleep Apnea [Internet]. Ento Key. 2017. Available from: https://entokey.com/pathophysiology-of-obstructive-sleep-apnea/
  3. Anatomy and Pathophysiology of Upper Airway Obstructive Sleep Apnoea: Review of the Current Literature [Internet]. Sleepmedres.org. 2021 [cited 2026 Mar 23]. Available from: https://sleepmedres.org/journal/view.php?viewtype=pubreader&number=175
  4. Sun H, Wu X, Ma G, Liu J, Guo X, Zhao Z. The relationship between obstructive sleep apnea and insulin resistance in patients with type 2 diabetes mellitus: a cross-sectional observational study. Journal of Thoracic Disease [Internet]. 2026 Feb [cited 2026 Mar 23];18(2):152–2. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12972757/
  5. Li J, Zeng L, Feng T. The Pathophysiological Relationship and Treatment Progress of Obstructive Sleep Apnea Syndrome, Obesity, and Metabolic Syndrome. Exploratory Research and Hypothesis in Medicine. 2025 Jan 7;000(000).
  6. Lam DCL, Lam KSL, Ip MSM. Obstructive sleep apnoea, insulin resistance and adipocytokines. Clinical Endocrinology. 2014 Oct 29;82(2):165–77
  7. Ciriello J, Moreau JM, Caverson MM, Moranis R. Leptin: A Potential Link Between Obstructive Sleep Apnea and Obesity. Frontiers in Physiology. 2022 Jan 27;12.
  8. Ursavas A, Ilcol Y, Nalci N, Karadag M, Ege E. Ghrelin, leptin, adiponectin, and resistin levels in sleep apnea syndrome: Role of obesity. Annals of Thoracic Medicine. 2010;5(3):161
  9. Imayama I, Prasad B. Role of Leptin in Obstructive Sleep Apnea. Annals of the American Thoracic Society. 2017 Nov;14(11):1607–21.
  10. Hartfield PJ, Janczy J, Sharma A, Newsome HA, Sparapani RA, Rhee JS, et al. Anatomical determinants of upper airway collapsibility in obstructive sleep apnea: A systematic review and meta-analysis. Sleep Medicine Reviews [Internet]. 2023 Apr 1 [cited 2023 Oct 3];68:101741. Available from: https://www.sciencedirect.com/science/article/abs/pii/S108707922200154X?via%3Dihub
  11. Welcome To Zscaler Directory Authentication [Internet]. Nih.gov. 2026. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9713906/
  12. Cai Z, Li J, Peng H, Ye Y, Chen S, Zeng L, et al. Non-linear association of the metabolic score for insulin resistance with obstructive sleep apnea: a cross-sectional study from NHANES 2015–2018. Frontiers in Nutrition [Internet]. 2025 Feb 26 [cited 2026 Mar 23];12. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11899179/
  13. Sara, Lorenzi‐Filho G, Drager LF. Obstructive sleep apnea and metabolic syndrome. 2023 Mar 2;31(4):900–11.
  14. Obstructive Sleep Apnea, Metabolic Syndrome and Diabetes – American College of Cardiology [Internet]. American College of Cardiology. 2026 [cited 2026 Mar 23]. Available from: https://www.acc.org/latest-in-cardiology/articles/2014/07/18/15/58/obstructive-sleep-apnea-metabolic-syndrome-and-diabetes
  15. Calvin AD, Albuquerque FN, Lopez-Jimenez F, Somers VK. Obstructive Sleep Apnea, Inflammation, and the Metabolic Syndrome. Metabolic Syndrome and Related Disorders [Internet]. 2009 Aug;7(4):271–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135895/
  16. Tasali E, Ip MSM. Obstructive Sleep Apnea and Metabolic Syndrome: Alterations in Glucose Metabolism and Inflammation. Proceedings of the American Thoracic Society. 2008 Feb 15;5(2):207–17.
  17. Adedayo AM, Olafiranye O, Smith D, Hill A, Zizi F, Brown C, et al. Obstructive sleep apnea and dyslipidemia: evidence and underlying mechanism. Sleep and Breathing. 2012 Aug 18;18(1):13–8.
  18. Trzepizur W, Le Vaillant M, Meslier N, Pigeanne T, Masson P, Humeau MP, et al. Independent Association Between Nocturnal Intermittent Hypoxemia and Metabolic Dyslipidemia. Chest. 2013 Jun;143(6):1584–9.
  19. Bajpai J, Pradhan A, Bajaj D, Kumar Verma A, Kant S, Pandey A, et al. Original Article Prevalence of dyslipidaemia in OSA patients at a tertiary care center. Am J Cardiovasc Dis [Internet]. 2023 [cited 2026 Mar 23];13(1):1–9. Available from: https://e-century.us/files/ajcd/13/1/ajcd0144452.pdf
  20. Chaput JP, McHill AW, Cox RC, Broussard JL, Dutil C, da Costa BGG, et al. The role of insufficient sleep and circadian misalignment in obesity. Nature Reviews Endocrinology. 2022 Oct 24;19(2).
  21. Michela Figorilli, Velluzzi F, Redolfi S. Obesity and Sleep Disorders: A Bidirectional Relationship. Nutrition Metabolism and Cardiovascular Diseases. 2025 Mar 1;35(6):104014–4.
  22. Pan W, Kastin AJ. Leptin: A biomarker for sleep disorders? Sleep Medicine Reviews. 2014 Jun;18(3):283–90.
  23. ŞAHİN T, TOZCU D. Circadian rhythm and obesity. International Journal of Science Letters. 2022 Feb 7;
  24. Engal E, Gileles-Hillel A. Epigenetic alterations in obstructive sleep Apnea: a pooled analysis of DNA methylation profiles in humans and animal models. Clinical Epigenetics [Internet]. 2025 Nov 19 [cited 2026 Mar 23];17(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12629001/
  25. Liu W, Zhang L, Liao W, Liu H, Liang W, Yan J, et al. Unveiling the molecular and cellular links between obstructive sleep apnea-hypopnea syndrome and vascular aging. Chinese Medical Journal [Internet]. 2024 Dec 6 [cited 2026 Mar 23];138(2):155–71. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11745861/
  26. With Persistent Treatment, Epigenetic Age Acceleration In Obstructive Sleep Apnea Can Be Reversed. – Sleephealth.org [Internet]. SleepHealth.org. 2022 [cited 2026 Mar 23]. Available from: https://www.sleephealth.org/2022/08/01/with-persistent-treatment-epigenetic-age-acceleration-in-obstructive-sleep-apnea-can-be-reversed/
  27. Jiang Y, Qu M, Cheng F, Sun H, Dai J, Wu Z. Correlation of telomere length and DNA damage markers with severity and associated depressive states in patients with OSAS. Frontiers in Neurology. 2025 Oct 20;16.
  28. Ma J, Chen M, Liu GH, Gao M, Chen NH, Toh CH, et al. Effects of sleep on the glymphatic functioning and multimodal human brain network affecting memory in older adults. Molecular Psychiatry [Internet]. 2024 Oct 14; Available from: https://www.nature.com/articles/s41380-024-02778-0
  29. Roy B, Nunez A, Aysola RS, Kang DW, Vacas S, Kumar R. Impaired Glymphatic System Actions in Obstructive Sleep Apnea Adults. Frontiers in Neuroscience. 2022 May 6;16.
  30. Carreras A, Zhang SX, Peris E, Qiao Z, Gileles-Hillel A, Li RC, et al. Chronic Sleep Fragmentation Induces Endothelial Dysfunction and Structural Vascular Changes in Mice. Sleep [Internet]. 2014 Nov 1 [cited 2020 Mar 20];37(11):1817–24. Available from: https://academic.oup.com/sleep/article/37/11/1817/2416752
  31. Picos A, Seoane N, Campos-Toimil M, Viña D. Vascular senescence and aging: mechanisms, clinical implications, and therapeutic prospects. Biogerontology. 2025 May 26;26(3).
  32. Roy B, Nunez A, Aysola RS, Kang DW, Vacas S, Kumar R. Impaired Glymphatic System Actions in Obstructive Sleep Apnea Adults. Frontiers in Neuroscience. 2022 May 6;16.
  33. Hayano J, Yamamoto H, Nonaka I, Komazawa M, Itao K, Ueda N, et al. Quantitative detection of sleep apnea with wearable watch device. Martin AR, editor. PLOS ONE. 2020 Nov 9;15(11):e0237279.
  34. Kim MW, Park SH, Choi MS. Diagnostic Performance of Photoplethysmography-Based Smartwatch for Obstructive Sleep Apnea. Journal of Rhinology [Internet]. 2022 Nov 30 [cited 2024 Apr 27];29(3):155–62. Available from: https://www.j-rhinology.org/upload/pdf/jr-2022-00424.pdf
  35. Cao S, Rosenzweig I, Bilotta F, Jiang H, Xia M. Automatic detection of obstructive sleep apnea based on speech or snoring sounds: a narrative review. Journal of Thoracic Disease. 2024 Apr 1;16(4):2654–67.
  36. Tartaglia FC, Pace GM, Giombi F, Nava G, Motisi A, Maffoni N, et al. Artificial Intelligence in Snoring Sound Analysis: OSA Detection and Obstruction Site Classification, a Systematic Review. Otolaryngology–Head and Neck Surgery. 2026 Jan 12;
  37. Alaa Abd-Alrazaq, Aslam H, Rawan AlSaad, Alsahli M, Ahmed A, Rafat Damseh, et al. Detection of Sleep Apnea Using Wearable AI: Systematic Review and Meta-Analysis. Journal of Medical Internet Research [Internet]. 2024 Sep 10;26:e58187–7. Available from: https://www.jmir.org/2024/1/e58187
  38. Huang J, Zhuang J, Zheng H, Yao L, Chen Q, Wang J, et al. A Machine Learning Prediction Model of Adult Obstructive Sleep Apnea Based on Systematically Evaluated Common Clinical Biochemical Indicators. Nature and Science of Sleep. 2024 Apr 1;Volume 16:413–28.
  39. Feng T, Ou Q, Shan G, Hu Y, He H. A predictive model for metabolic syndrome in a community-based population with sleep apnea: a secondary prevention screening tool using simple and accessible indicators. Frontiers in Nutrition. 2025 Nov 5;12.
  40. Dai R, Yang K, Zhuang J, Yao L, Hu Y, Chen Q, et al. Enhanced machine learning approaches for OSA patient screening: model development and validation study. Scientific Reports [Internet]. 2024 Aug 26;14(1). Available from: https://www.nature.com/articles/s41598-024-70647-5#Sec13
  41. Li S, Huang J, Xiao Z, Fan C. Advances in Machine Learning Prediction Models for the Screening of Obstructive Sleep Apnea in Adults. Nature and Science of Sleep. 2025 Oct 1;Volume 17:2575–95.
  42. Shah RM, Sethi JM, Wolf L, LaCavera M, Koo P. Obstructive Sleep Apnea: Strategies for Screening, Management, and Overcoming Treatment Challenges in the Outpatient Setting. American Journal of Lifestyle Medicine [Internet]. 2023 Nov 24; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12177834/
  43. Choudhury N, Deshmukh P. Obstructive Sleep Apnea in Adults and Ear, Nose, and Throat (ENT) Health: A Narrative Review. Cureus [Internet]. 2023 Oct 25; Available from: https://assets.cureus.com/uploads/review_article/pdf/184127/20231124-18404-1hjqtfl.pdf
  44. Feltner C, Wallace IF, Aymes S, Cook Middleton J, Hicks KL, Schwimmer M, et al. Screening for Obstructive Sleep Apnea in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA [Internet]. 2022 Nov 15;328(19):1951–71. Available from: https://jamanetwork.com/journals/jama/article-abstract/2798400
  45. Obstructive Sleep Apnea: Assessment and Management in Adults [Internet]. 2021. Available from: https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/doctorsbc-sleepapnea-guideline-2021-v2.pdf
  46. Carneiro-Barrera A, Amaro-Gahete FJ, Guillén-Riquelme A, Jurado-Fasoli L, Sáez-Roca G, Martín-Carrasco C, et al. Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity. JAMA Network Open. 2022 Apr 22;5(4):e228212.
  47. Kuna ST, Reboussin DM, Strotmeyer ES, Millman RP, Zammit G, Walkup MP, et al. Effects of Weight Loss on Obstructive Sleep Apnea Severity. Ten-Year Results of the Sleep AHEAD Study. American Journal of Respiratory and Critical Care Medicine. 2021 Jan 15;203(2):221–9.
  48. Malhotra A, Heilmann CR, Banerjee KK, Dunn JP, Bunck MC, Bednarik J. Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis. Sleep Medicine. 2024 Sep 1;121:26–31.
  49. Rueda JR, Mugueta-Aguinaga I, Vilaró J, Rueda-Etxebarria M. Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea. Cochrane Database of Systematic Reviews. 2020 Nov 3;
  50. Correia S, Gonzalez M, Deger M, Pitts P. The Value of Implementing a Digital Approach in the Obstructive Sleep Apnoea Patient Pathway: A Spanish Example. Open Respiratory Archives. 2024 Jan;6(1):100289.
  51. Haverinen J, Harju T, Mikkonen H, Liljamo P, Turpeinen M, Reponen J. Digital Care Pathway for Patients With Sleep Apnea in Specialized Care: Mixed Methods Study. JMIR Human Factors [Internet]. 2024 Feb 22 [cited 2024 May 27];11(1):e47809. Available from: https://humanfactors.jmir.org/2024/1/e47809

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading